Loading...
OTCM
TBRIF
Market cap2mUSD
Jun 22, Last price  
0.03USD
Name

Therma Bright Inc

Chart & Performance

D1W1MN
OTCM:TBRIF chart
P/E
P/S
36.76
EPS
Div Yield, %
Shrs. gr., 5y
-19.29%
Rev. gr., 5y
84.22%
Revenues
80k
+207.90%
43,810770,029250,858251,019172,75200001,7094,79331,16314,0966,9053,7833,883139,42723,89926,07080,269
Net income
-3m
L+27.87%
-1,149,512-1,835,083-1,608,172-2,103,331-1,513,874-617,308-735,429860,04468,208-356,371-206,021-965,589-1,236,154-421,931-626,682-8,610,322-5,881,072-3,767,772-2,451,307-3,134,579
CFO
-147k
L-85.48%
-511,692-1,314,005-539,115-365,580-62,678-15,996-435-84,101-55,164-21,42554-178,487-359,890-189,723-104,944-2,855,507-3,800,002-2,174,861-1,009,279-146,529

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Based in Toronto, Canada, Therma Bright Inc., established in 2001 and formerly known as The Jenex Corporation until its rebranding in 2018, specializes in the creation and commercialization of a diverse portfolio of medical and consumer health devices. Their offerings include rapid diagnostic tests for COVID-19, such as AcuVid, which screens for both antigens and antibodies. The company also provides innovative solutions for pain management and other health concerns, featuring InterceptCS, a system utilizing controlled topical heat to prevent cold sores, and Benepod, a hot and cold contrast therapy device designed for drug-free pain relief. Furthermore, they offer the Venowave medical compression pump to treat symptoms associated with poor circulation. For insect bites and stings, Therma Bright produces TherOZap, a thermal therapy device that effectively reduces inflammatory responses, itching, and pain. Their products cater to a broad market, serving both general consumers and healthcare professionals.
IPO date
Jul 11, 2001
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑072024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑07
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT